SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of MannKind Corp. of Class Action Lawsuit and a Lead Plaintiff Deadline of March 15, 2016 – MNKD

NEW YORK, March 11, 2016 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of MannKind Corporation ("MannKind" or the "Company") MNKD between August 10, 2015 and January 5, 2016.   

You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Central District of California. If you purchased or otherwise acquired MannKind securities between August 10, 2015 and January 5, 2016, your rights may be affected by this action. To get more information go to:

http://zlk.9nl.com/mannkind

or contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.

The complaint alleges that throughout the Class Period Defendants issued false and misleading statements and/or failed to disclose that: (1) contrary to Defendants' assurances, the mandated pulmonary testing or spirometry was still a significant issue impeding sales of Afrezza, the Company's rapid-acting insulin; and (2) as a result, Defendants' statements about MannKind's business, operations, and prospects, were false and misleading and/or lacked a reasonable basis at all relevant times.

If you suffered a loss in MannKind you have until March 15, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, California, Connecticut and Washington D.C. The firm's attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.